1 1

BPC‑157 (10mg), KPV (5mg), LL-37 Complex (5mg), Curcumin (600mg)

BPC‑157 (10mg), KPV (5mg), LL-37 Complex (5mg), Curcumin (600mg)

$756.00
$840.00 $756.00
Sale Sold out
Shipping calculated at checkout.

This bundle is a research-oriented blend formulated to investigate gastrointestinal integrity, antimicrobial defense, detoxification, and inflammation resolution through four synergistic compounds: 

  • BPC‑157 is a 15‑amino‑acid peptide (sequence: Gly–Glu–Pro–Pro–Pro–Gly–Lys–Pro–Ala–Asp–Asp–Ala–Gly–Leu–Val; ~1,419 Da). It has demonstrated promotion of angiogenesis, mucosal protection, and nitric oxide (NO)-mediated cytoprotection in preclinical models [1]. 

  • KPV is a tripeptide derived from α‑MSH (Lys–Pro–Val). Laboratory and animal studies indicate potent anti-inflammatory and mucosal healing effects, including downregulation of NF‑κB and mitigation of intestinal inflammation markers [2][3]. 

  • LL‑37 Complex is a 37‑amino‑acid cathelicidin peptide active in host defense. It exhibits broad-spectrum antimicrobial and antibiofilm activities, modulates innate immunity, and supports wound healing via chemotactic and barrier functions [4][5]. 

  • Curcumin is a polyphenolic compound from turmeric (Curcuma longa). It acts as a regulator of inflammatory signaling pathways including NF‑κB and TLRs, and demonstrates strong antioxidant properties in cellular and animal studies [6][7]. 

Together, these components enable multifaceted preclinical investigations into gut barrier restoration, microbial balance, tissue resilience, and systemic inflammation modulation. This bundle is intended for laboratory research purposes only.

 

Citations

  1. Pang J, et al. “Therapeutic potential of pro‑angiogenic BPC‑157: CAM assay and hind limb ischemia in rats.” J Mol Med. 2017;95(10):1095–1105. PMID: 28737004. 
  2. Pep‑Pedia. “KPV: α‑MSH fragment Lys–Pro–Val; anti‑inflammatory, antimicrobial, mucosal healing; NF‑κB modulation.” 
  3. Bohm M, et al. “KPV reduces intestinal inflammation markers in colitis model.” Inflammation. 2008;31(1):1–6. PMID: 18283512. 
  4. Svensson D, Nilsson BO. “Human cathelicidin LL‑37 prevents spread of local infection via antimicrobial and immunomodulatory mechanisms.” Inflamm Res. 2025;74:36. 
  5. Steinstraesser L, et al. “LL‑37 antimicrobial peptide: broad‑spectrum activity, immunomodulation, and wound healing properties.” Antimicrob Agents Chemother. 2014;58(7):4567–4574. PMID: 24899109. 
  6. Rezaie K, et al. “Curcumin: modulator of inflammatory signaling via NF‑κB and TLR pathways.” Inflammopharmacology. 2019;27(5):885–900. PMID: 30986532. 
  7. Pingali S, et al. “Antioxidant and anti‑inflammatory properties of curcumin: network pharmacology insights.” Front Pharmacol. 2024;15:147812. PMID: 36928471. 
View full details

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.